Cadrenal Therapeutics Inc. (CVKD)

Overview

Cadrenal Therapeutics, Inc. is a pioneering biopharmaceutical company engaged in the clinical development of innovative drug solutions. With a strategic focus on addressing the unmet medical needs of patients suffering from rare cardiovascular conditions, Cadrenal Therapeutics is at the forefront of discovering novel therapeutic pathways. The company's mission revolves around the prevention of heart attacks, strokes, and blood clot-induced fatalities through the development of Tecarfarin, a novel oral and reversible anticoagulant. Established in 2022 and based in Ponte Vedra, Florida, Cadrenal Therapeutics combines cutting-edge scientific research with clinical expertise to improve patient outcomes in chronic anticoagulation therapy.

Products and Services

• Tecarfarin

  A groundbreaking oral and reversible anticoagulant, Tecarfarin is being developed to mitigate the risk of heart attacks, strokes, and deaths associated with blood clots in patients afflicted with rare cardiovascular conditions. This includes, but is not limited to, patients who require chronic anticoagulation therapy. The drug's target demographics encompass individuals with left ventricular assist devices (LVADs), those undergoing the challenges of end-stage kidney disease, patients diagnosed with atrial fibrillation, and those suffering from thrombotic anti-phospholipid syndrome. Tecarfarin's innovative approach lies in its potential to offer a safer, more effective anticoagulation option that specifically caters to the needs of patients for whom conventional therapies may not be suitable or sufficient.